Free Trial
NASDAQ:ATXI

Avenue Therapeutics 8/9/2024 Earnings Report

Avenue Therapeutics logo
$0.26 +0.00 (+0.04%)
As of 09:32 AM Eastern

Avenue Therapeutics EPS Results

Actual EPS
-$6.43
Consensus EPS
-$1.05
Beat/Miss
Missed by -$5.38
One Year Ago EPS
N/A

Avenue Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avenue Therapeutics Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Avenue Therapeutics' next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules.

Conference Call Resources

Avenue Therapeutics Earnings Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Avenue Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avenue Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avenue Therapeutics and other key companies, straight to your email.

About Avenue Therapeutics

Avenue Therapeutics (NASDAQ:ATXI), a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

View Avenue Therapeutics Profile

More Earnings Resources from MarketBeat